Latest News: The upcoming vaccine, Corbevax by Biological E. is expected to be the cheapest vaccine on Indian market at Rs.500 for 2 doses. The vaccine is currently undergoing its Phase III clinical trials and will be soon authorized an emergency use approval.
The Union Ministry of Health and Family Welfare finalized an arrangement to procure 30 crore doses of the Corbevax from the Hyderabad-based Biological E Ltd on Thursday which is developed in association with Baylor College of Medicine in U.S, modelled after the Hepatitis B vaccines.
The vaccine is said to have shown promising results of efficiency in the Phase I and Phase II clinical trials and is a RBD protein sub-unit vaccine. The company got its permission to conduct Phase III trials from Central Drugs and Standard Control Organization (CDSCO) back in the month of April.
Apart from its association with Baylor College to make Corbevax, the company has also partnered with a Canada-based Providence Therapeutics Holdings Ltd to make a mRNA vaccine – PTX-COVID-19 in India. The company will handle all clinical developments and regulatory activities under the jurisdiction of our country and others as well that licenses it.
Biological E targets to produce one billion units of the mRNA vaccine in India by 2022, with Providence providing necessary technology transfer. Biological E targets a minimum of 600 million and maximum of 1 billion doses to be produced by the end of 2022, read a company statement.
While AstraZeneca-SII’s Covishield is sold for Rs.600 for two doses to the Central Government and double – Rs.1200 for two doses to private hospitals, Bharat Biotech’s Covaxin for Rs.800 – Rs.2,400 and RDIF’s Sputnik V for Rs.995 Biological E’s vaccine maybe the cheapest of all at just Rs.500 or less for two doses.